Active Ingredient History
Acenocoumarol is mono-coumarin derivative with racemic mixture of R (+) and S (-) enantiomers. Acenocoumarol is structurally similar to vitamin K and is competitively able to inhibit the enzyme vitamin K-epoxide reductase. It exerts anticoagulant action by preventing the regeneration of reduced vitamin K by interfering with action of vitamin K epoxide reductase. Acenocoumarol is prescribed as the anticoagulant in various thromboembolic disorders. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Anticoagulants (Phase 2/Phase 3)
Antiphospholipid Syndrome (Phase 3)
Atrial Fibrillation (Phase 4)
Atrial Flutter (Phase 3)
Blood Coagulation Disorders (Phase 4)
Cerebral Intraventricular Hemorrhage (Phase 3)
Cerebrovascular Disorders (Phase 3)
Diabetes Mellitus (Phase 4)
Heart Valve Diseases (Phase 4)
Hematoma, Subdural (Phase 3)
Hemorrhage (Phase 3)
Intracranial Hemorrhage, Hypertensive (Phase 3)
Intracranial Hemorrhages (Phase 3)
Melanoma (Phase 1)
Neoplasms (Phase 3)
Percutaneous Coronary Intervention (Phase 3)
Pulmonary Embolism (Phase 4)
Stroke (Phase 4)
Subarachnoid Hemorrhage (Phase 3)
Thrombosis (Phase 4)
Venous Thromboembolism (Phase 4)
Venous Thrombosis (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue